Results 1 to 10 of about 2,752 (194)

From COPD to cancer: indacaterol’s unexpected role in combating NSCLC [PDF]

Frontiers in Pharmacology
BackgroundNon-small cell lung cancer (NSCLC) is one of the most prevalent and deadly malignancies worldwide. In previous studies, indacaterol, a drug used to manage chronic obstructive pulmonary disease, has shown antitumor activity. However, its role in
Chenghao Liu, Jiaqi Huang, Pengjie Cai, Pengjie Cai, Min Jiang, Honglei Chen, Honglei Chen   +6 more
doaj   +2 more sources

Pharmacokinetics of pulmonary indacaterol in rat lung using molecular imprinting solid-phase extraction coupled with RP-UPLC [PDF]

Scientific Reports
Indacaterol, a β2 agonist prescribed for long-term management of patients with chronic obstructive pulmonary disease and asthma. In this study the first MISPE cartridges was developed using indacaterol as a template for its selective extraction from rat ...
Mohamed Tarek, Nermine S. Ghoniem, Maha A. Hegazy, Hebatallah A. Wagdy   +3 more
doaj   +2 more sources

Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials. [PDF]

PLoS ONE, 2015
Two once-daily inhaled bronchodilators, indacaterol and tiotropium, are widely used as first-line therapy in stable COPD patients. This study was performed to compare the clinical efficacy and safety between indacaterol and tiotropium in patients with ...
Jung Soo Kim, Jinkyeong Park, Seong Yong Lim, Yeon-Mok Oh, Kwang Ha Yoo, Yong Bum Park, Seung Soo Sheen, Min-Ji Kim, K C Carriere, Ji Ye Jung, Hye Yun Park   +10 more
doaj   +1 more source

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials

ERJ Open Research, 2021
Inhaled corticosteroids have proven to be less effective in asthmatic patients who smoke; however, there is limited information on the efficacy of inhaled corticosteroid-containing regimens in COPD patients who continue smoking.
David M.G. Halpin, Claus F. Vogelmeier, Karen Mezzi, Pritam Gupta, Konstantinos Kostikas, Jadwiga A. Wedzicha   +5 more
doaj   +1 more source

Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients

Respiratory Research, 2020
Background Indacaterol maleate delivered with the Breezhaler® inhalation device is a long-acting β2-agonist approved for chronic obstructive pulmonary disease.
David Miller, Soniya Vaidya, Juergen Jauernig, Brian Ethell, Kristina Wagner, Rajkumar Radhakrishnan, Hanns-Christian Tillmann   +6 more
doaj   +1 more source

Effects of (a Combination of) the Beta₂-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction

Cells, 2021
Expression of bronchodilatory β2-adrenoceptors and bronchoconstrictive muscarinic M3-receptors alter with airway size. In COPD, (a combination of) β2-agonists and muscarinic M3-antagonists (anticholinergics) are used as bronchodilators.
Harm Maarsingh, Anouk Oldenburger, Bing Han, Annet B. Zuidhof, Carolina R. S. Elzinga, Wim Timens, Herman Meurs, Ramadan B. Sopi, Martina Schmidt   +8 more
doaj   +1 more source

Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

BMC Pulmonary Medicine, 2010
Background Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting β2-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that ...
Piggott Simon, Jack Damon, Prasad Niyati, Siler Thomas, Feldman Gregory, Owen Roger, Higgins Mark, Kramer Benjamin   +7 more
doaj   +1 more source

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium

Respiratory Research, 2010
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that of ...
Owen Roger, Piggott Simon, Jack Damon, Ramos-Barbon David, Vogelmeier Claus, Higgins Mark, Kramer Benjamin   +6 more
doaj   +1 more source

Profiling the bronchodilator effects of the novel ultra-long-acting β-agonist indacaterol against established treatments in chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease, 2011
Indacaterol is a novel, inhaled, ultra-long-acting β 2 -agonist providing 24-h bronchodilation with once-daily (od) dosing for maintenance use in patients with chronic obstructive pulmonary disease (COPD).
Claus Vogelmeier, Helgo Magnussen, Craig LaForce, Roger Owen, Benjamin Kramer   +4 more
doaj   +1 more source

Bronchodilator Efficacy of Single Doses of Indacaterol in Japanese Patients with COPD: A Randomised, Double-Blind, Placebo-Controlled Trial

Allergology International, 2010
: Background: Indacaterol is an investigational, novel, inhaled once-daily ultra-long-acting beta-2 agonist for the treatment of chronic obstructive pulmonary disease (COPD).
Motokazu Kato, Hironi Makita, Koji Uemura, Yoshinosuke Fukuchi, Motoi Hosoe, Charlotte Emery, Mark Higgins, Benjamin Kramer   +7 more
doaj   +1 more source